Leaders of the Global Liquid Biopsy Revolution

As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD).

SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.

Biotechnology

Life Sciences

Pharmaceutical

Sysmex Inostics

Shinichi Sato

Jacob Claussen

Msph Anita Talley

Jen Swindell (Preston)

Laura Gauglitz

Inga Medina Diaz

Katharina Wichner

Kellie Quash

Papa Kofi F. Baffour-Awuah

Karen Bezold

Takeisha Farmer

María Esteban López

Johannes Fredebohm

Frederick Jones

Yosuke Baba

Jennifer McCord

Karin Ballas

The Research and Scientific Development team at Sysmex Inostics focuses on advancing liquid biopsy technology by developing and validating high-sensitivity assays for detecting tumor DNA mutations in blood samples. They work on creating innovative diagnostic tools for monitoring therapy responses, identifying resistance mutations, and detecting minimal residual disease (MRD). This multidisciplinary team of scientists, research associates, and bioinformaticians collaborates to enhance the capability and accuracy of the SafeSEQ NGS technology, ensuring it meets clinical needs and supports therapeutic development.

Research and Scientific Development

Clinical and Laboratory Team

Project Management

Research and Scientific Development

About

Team members

Other teams at Sysmex Inostics

Clinical and Laboratory Team

Project Management